Mark Rutstein’s Post

I previously shared that Daiichi Sankyo will present new clinical research across its DXd antibody drug conjugate (ADC) portfolio during the International Association for the Study of Lung Cancer 2023 World Conference on Lung Cancer. The immense potential of the Daiichi Sankyo, Inc. pipeline is enabling the organization to expand research across a variety of different tumor types. There was one session during #WCLC23 that uniquely represented the promise and potential of our DXd ADC strategy called “Antibody Drug Conjugates: The Next Tsunami.” This was the first time ever where three Daiichi Sankyo ADCs were featured together in one session with new data from our HERTHENA-Lung01 and TROPION-Lung04 trials along with a subgroup analysis of a phase 1/2 study. ADCs are already changing the standard of care and the prognosis for patients and sessions like this continue to explore and demonstrate the potential of these medicines for patients. #oncologyresearch